There are about 25228 clinical studies being (or have been) conducted in United Kingdom. The country of the clinical trial is determined by the location of where the clinical research is being studied. Most studies are often held in multiple locations & countries.
Continuation study to provide continued access to latozinemab for participants who have previously participated in a latozinemab study
The goal of this mixed methods observational study is to investigate paramedic independent prescribing (PIP) in emergency and urgent healthcare settings. The main questions it aims to answer are: 1. What are benefits and limitations of paramedic independent prescribing in emergency and urgent care settings and how does it contribute to patient care and healthcare service delivery? 2. What facilitators and barriers exist which influence the implementation and delivery of PIP as a new and complex intervention within emergency and urgent care? Participants in the study will include paramedics qualified in PIP and staff working at the case study sites. With participant consent, data will be collected using non-participant observation of the prescribing practice of 4-6 paramedics at each site, capturing this data through field notes. The views and insights of a range of other site staff such as managers, doctors and other clinicians will be interviewed at each case site, during semi structured interviews. At each case site anonymised prescribing frequency data will also be collected to understand the range and frequencies of prescribed medication by paramedics. Relevant meetings (such as clinical governance and medicines management meetings) will also be observed, and documentary analysis of relevant site documents will also be undertaken.
The goal of this study is to evaluate safety and performance of the Fortiva Tissue Matrix. Participants will complete questionnaires to measure outcomes after hernia surgery for two years.
The investigators will conduct low-dose intranasal allergen challenges on children and young people with an indeterminate diagnosis of food allergy to cow's milk or peanut. Blood samples will also be taken, for conventional blood allergy diagnostics (allergy-specific Immunoglobulin E) and mast cell activation test (MAT). The data will be used to determine the diagnostic accuracy of two complementary, novel approaches to diagnose food allergy, in a representative clinical cohort.
Congenital Portosystemic Shunt (CPSS) is a rare condition important by the multiplicity and severity of associated complications. CPSS is venous anomaly in which blood coming from the intestines only partially passes through the liver. This leads to the accumulation of potentially toxic factors that cause systemic effects. Complications vary among the individuals, and currently, it is challenging to predict which individuals will develop severe complications. The IRCPSS registry is established with the aim of centralizing detailed clinical follow-up and biological information from participants around the world who suffer from Congenital Portosystemic Shunt (CPSS). A multidisciplinary consortium of experts is collaborating to enhance our understanding of the prevalence, natural history, individual risks, and physiopathology of the disease through the IRCPSS registry.
This study aims to create a comprehensive Magnetic Resonance Imaging data resource in twins aged 18 years and older. The data will be used alone or in conjunction with existing data to explore organ-specific ageing and twin-pair differences related to ageing and disease.
Aims of the study: - To measure the rate of completion of a digital cardiac rehabilitation programme at Imperial College Healthcare NHS Trust (ICHNT) - To measure the health economic impact of a digital cardiac rehabilitation programme at ICHNT Any adult patient eligible for ICHNT cardiac rehabilitation (CR) programmes is eligible to participate. Participants will receive a commercially available smart watch and be asked to wear the device as much as possible. In addition, they will be asked to download a smartphone application called 'Imperial Healthy Hearts', which displays movement and information on heart rate, breathing and oxygen levels to both the participant and the research team (digital data). The Healthy Hearts app also allows the direct care team to provide educational materials to patients as part of their routine care. The clinical content and structure of the CR programme is determined by the clinical CR team, and does not deviate from established local and national standards and practices. Researchers will capture physiological data such as heart rate, respiratory rate, blood pressure (where available) and oxygen saturation (where available) via the Healthy Hearts platform. Researchers will also capture clinical information from the electronic health record, and will compare CR programme uptake and completion rates with historical data and national targets.
Aims of the study: 1. To deliver a scalable wellbeing programme to the local population of Imperial College Healthcare NHS Trust, focusing on movement. 2. To describe the natural history of long-term conditions using digital data from a smartwatch. 3. To identify digital information that is routinely collected by a smart watch that can be used to predict outcomes in patients with long term conditions. 4. To identify factors that determine whether participants engage with and improve in a movement programme. Adult patients who are registered to the Imperial NHS Care Information Exchange (CIE), an NHS patient-facing electronic health record, are eligible to participate in the study. Participants will receive a smart watch for self-monitoring of their movement and wellbeing and be asked to wear the device as much as possible. They will be asked to download a smartphone application called Connected Life, which displays movement and information on heart rate, breathing and oxygen levels to both the participant and the research team (digital data). Participants will receive secure login details for the Connected Life application from the research team, to ensure data privacy. The research team will look at participants' health records, and attempt to identify associations between the digital data and clinical information. This will allow the research team to identify digital data that predicts the onset and natural history of long term conditions, which may potentially allow for earlier diagnosis for future patients. The primary outcome of the study is the identification of trends in movement based on step-count data recorded by the smartwatch.
FutureMS is a project created in direct response to frequent questions people with MS ask their doctors. Every person newly diagnosed wants to know how MS will affect them over their life and what can be done to stop the disease progressing and improve their quality of life. FutureMS aims to help answer those questions. The original FutureMS study provided a snapshot of the impact of MS within a year of diagnosis. However, MS is a long-term condition and so the investigators now want to better understand the impact of MS, on the same individuals, after approximately 5 and 10 years of living with MS. This is the purpose of FutureMS-2.
This long-term follow-up study is being conducted to collect long-term (up to 15 years post-infusion) safety and tolerability data from subjects enrolled in studies evaluating TX200-TR101.